These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30676789)

  • 41. Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020).
    Dana SR; Nichols SD; McCall KL; Piper BJ
    J Stud Alcohol Drugs; 2024 Jan; 85(1):19-25. PubMed ID: 37650858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
    Knudsen HK; Hartman J; Walsh SL
    Drug Alcohol Depend; 2022 Mar; 232():109336. PubMed ID: 35123365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
    Sharp A; Jones A; Sherwood J; Kutsa O; Honermann B; Millett G
    Am J Public Health; 2018 May; 108(5):642-648. PubMed ID: 29565661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases.
    Hsu ZS; Warnick JA; Harkins TR; Sylvester BE; Bharati NK; Eley LB; Nichols SD; McCall K; Piper BJ
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01115. PubMed ID: 37485957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 48. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 49. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
    Stein BD; Saloner BK; Golan OK; Andraka-Christou B; Andrews CM; Dick AW; Davis CS; Sheng F; Gordon AJ
    JAMA Health Forum; 2023 May; 4(5):e231102. PubMed ID: 37234015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status.
    Sanmartin MX; Ali MM; Dwyer DS
    Subst Abus; 2022 Dec; 43(1):1072-1074. PubMed ID: 35442126
    [No Abstract]   [Full Text] [Related]  

  • 51. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
    Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
    J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.
    Knudsen HK
    J Stud Alcohol Drugs; 2015 Jul; 76(4):644-54. PubMed ID: 26098042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
    Tilhou AS; Dague L; Saloner B; Beemon D; Burns M
    JAMA Health Forum; 2022 Mar; 3(3):e220093. PubMed ID: 35977284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine.
    Nguemeni Tiako MJ; Culhane J; South E; Srinivas SK; Meisel ZF
    JAMA Netw Open; 2020 Dec; 3(12):e2029043. PubMed ID: 33306115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
    Jaffe JH; O'Keeffe C
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spillover of Medicaid Expansion to Prescribing of Opioid Use Disorder Medications in Medicare Part D.
    Abraham AJ; Lawler EC; Harris SJ; Bagwell Adams G; Bradford WD
    Psychiatr Serv; 2022 Apr; 73(4):418-424. PubMed ID: 34407628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in Buprenorphine to Treat Opioid Use Disorder in California, 2012 to 2018: Medicaid Outpaces the Rest of the State.
    Tseregounis IE; Gasper JJ; Henry SG
    J Addict Med; 2021 Sep-Oct 01; 15(5):425-428. PubMed ID: 33186262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.